Safety and efficacy of the Russian COVID-19 vaccine: more information needed

doi:10.1016/S0140-6736(20)31960-7

Comment

. 2020 Oct 3;396(10256):e53.

doi: 10.1016/S0140-6736(20)31960-7. Epub 2020 Sep 21.

Safety and efficacy of the Russian COVID-19 vaccine: more information needed

Enrico Bucci¹, Konstantin Andreev², Anders Björkman³, Raffaele Adolfo Calogero⁴, Ernesto Carafoli⁵, Piero Carninci⁶, Paola Castagnoli⁷, Andrea Cossarizza⁸, Cristina Mussini⁸, Philippe Guerin⁹, Brian Lipworth¹⁰, Gianluca Sbardella¹¹, Teresa Stocki¹², Loretta Tuosto¹³, Christoffer van Tulleken¹⁴, Antonella Viola¹⁵

Affiliations

¹ Sbarro Health Research Organization, Temple University, Philadelphia, PA, USA; Resis Srl, 10010 Samone, Italy. Electronic address: enrico.bucci@resis-srl.com.
² Northwestern University, Evanston, IL, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
³ Karolinska Institutet, Stockholm, Sweden.
⁴ University of Turin, Tornio, Italy.
⁵ Accademia Nazionale dei Lincei, Rome, Italy.
⁶ RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
⁷ Toscana Life Sciences Foundation, Siena, Italy.
⁸ University of Modena and Reggio Emilia, Modena, Italy.
⁹ University of Oxford, Oxford, UK.
¹⁰ University of Dundee, Dundee, UK.
¹¹ University of Salerno, Fisciano, Italy.
¹² Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.
¹³ Sapienza University of Rome, Rome, Italy.
¹⁴ University College London, London, UK.
¹⁵ University of Padua, Padua, Italy.

PMID: 32971041
PMCID: PMC7503114
DOI: 10.1016/S0140-6736(20)31960-7

Comment

Safety and efficacy of the Russian COVID-19 vaccine: more information needed

Enrico Bucci et al. Lancet. 2020.

. 2020 Oct 3;396(10256):e53.

doi: 10.1016/S0140-6736(20)31960-7. Epub 2020 Sep 21.

Authors

Affiliations

¹ Sbarro Health Research Organization, Temple University, Philadelphia, PA, USA; Resis Srl, 10010 Samone, Italy. Electronic address: enrico.bucci@resis-srl.com.
² Northwestern University, Evanston, IL, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
³ Karolinska Institutet, Stockholm, Sweden.
⁴ University of Turin, Tornio, Italy.
⁵ Accademia Nazionale dei Lincei, Rome, Italy.
⁶ RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
⁷ Toscana Life Sciences Foundation, Siena, Italy.
⁸ University of Modena and Reggio Emilia, Modena, Italy.
⁹ University of Oxford, Oxford, UK.
¹⁰ University of Dundee, Dundee, UK.
¹¹ University of Salerno, Fisciano, Italy.
¹² Leeds Teaching Hospitals National Health Service Trust, Leeds, UK.
¹³ Sapienza University of Rome, Rome, Italy.
¹⁴ University College London, London, UK.
¹⁵ University of Padua, Padua, Italy.

PMID: 32971041
PMCID: PMC7503114
DOI: 10.1016/S0140-6736(20)31960-7

No abstract available

PubMed Disclaimer

Comment on

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Logunov DY, et al. Lancet. 2020 Sep 26;396(10255):887-897. doi: 10.1016/S0140-6736(20)31866-3. Epub 2020 Sep 4. Lancet. 2020. PMID: 32896291 Free PMC article. Clinical Trial.

Cited by

Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort.
Blanco S, Salomé Konigheim B, Diaz A, Spinsanti L, Javier Aguilar J, Elisa Rivarola M, Beranek M, Collino C, MinSalCba Working Group, Fcm-Unc Working Group, Diaz M, Gabriela Barbás M, Mangeaud A, Verónica Gallego S. Blanco S, et al. Vaccine. 2022 Jan 31;40(5):811-818. doi: 10.1016/j.vaccine.2021.12.027. Epub 2021 Dec 20. Vaccine. 2022. PMID: 34953609 Free PMC article.
Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study.
Barchuk A, Cherkashin M, Bulina A, Berezina N, Rakova T, Kuplevatskaya D, Stanevich O, Skougarevskiy D, Okhotin A. Barchuk A, et al. BMC Med. 2022 Sep 20;20(1):312. doi: 10.1186/s12916-022-02509-8. BMC Med. 2022. PMID: 36123681 Free PMC article. Clinical Trial.
Willingness to Receive COVID-19 Vaccination in Japan.
Yoda T, Katsuyama H. Yoda T, et al. Vaccines (Basel). 2021 Jan 14;9(1):48. doi: 10.3390/vaccines9010048. Vaccines (Basel). 2021. PMID: 33466675 Free PMC article.
Ethnic and minority group differences in engagement with COVID-19 vaccination programmes - at Pandemic Pace; when vaccine confidence in mass rollout meets local vaccine hesitancy.
Reid JA, Mabhala MA. Reid JA, et al. Isr J Health Policy Res. 2021 May 27;10(1):33. doi: 10.1186/s13584-021-00467-9. Isr J Health Policy Res. 2021. PMID: 34044891 Free PMC article.
The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland.
Rzymski P, Zeyland J, Poniedziałek B, Małecka I, Wysocki J. Rzymski P, et al. Vaccines (Basel). 2021 Apr 14;9(4):382. doi: 10.3390/vaccines9040382. Vaccines (Basel). 2021. PMID: 33919672 Free PMC article.

See all "Cited by" articles

References

1. Logunov DY, Dolzhikova I, V, Zubkova O., V Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 doi: 10.1016/S0140-6736(20)31866-3. published online Sept 4. - DOI - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

MR/J011533/1/MRC_/Medical Research Council/United Kingdom

LinkOut - more resources

Full Text Sources

[1] Logunov DY, Dolzhikova I, V, Zubkova O., V Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 doi: 10.1016/S0140-6736(20)31866-3. published online Sept 4. - DOI - PMC - PubMed

[2] Logunov DY, Dolzhikova I, V, Zubkova O., V Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 doi: 10.1016/S0140-6736(20)31866-3. published online Sept 4. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Safety and efficacy of the Russian COVID-19 vaccine: more information needed

Affiliations

Safety and efficacy of the Russian COVID-19 vaccine: more information needed

Authors

Affiliations

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources